XML 79 R62.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Stock Options Issued and Outstanding Activities (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]      
Number of Stock Options Outstanding, Beginning 2,565,377 [1] 1,419,242  
Weighted Average Exercise Price, Ending $ 3.14 [1] $ 0.73  
Remaining Contractual Term (Years) 8 years 6 months [1] 8 years 3 months 18 days [1] 7 years
Number of Stock Options, Granted [2] 3,618,000 2,365,000  
Weighted Average Exercise Price, Granted [2] $ 1.32 $ 3.68  
Number of Stock Options, Exercised (965,342)  
Weighted Average Exercise Price, Exercised $ 0.72  
Number of Stock Options, Forfeited (678,994) (253,523)  
Weighted Average Exercise Price, Forfeited $ 2.75 $ 3.83  
Intrinsic Value, Beginning [3] $ 428    
Number of Stock Options Outstanding, Ending 5,504,383 [1] 2,565,377 [1] 1,419,242
Weighted Average Exercise Price, Ending $ 2.00 [1] $ 3.14 [1] $ 0.73
Intrinsic Value, Ending [3] $ 765 [1] $ 428  
Number of Stock Options, Vested and exercisable 2,339,527    
Weighted Average Exercise Price, Vested and exercisable stock options $ 2.30    
Remaining Contractual Term (Years), Vested and Exercisable 7 years 9 months 18 days    
Intrinsic Value, Vested and exercisable [3] $ 529    
[1] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics 2018 Equity Plan, as of December 31, 2023 and December 31, 2022.
[2] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.
[3] The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of December 31, 2023 and December 31, 2022 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.